Instrument Inactif

Communiqués Arcede Pharma AB

Actions

ARCEDE

SE0018168742

Communiqués

04/07/24	BioStock: Arcede Pharma heading towards liquidation	AQ
22/05/24	BioStock: Full focus on financing and new CEO for Arcede	AQ
10/05/24	BioStock: New results confirmation for Arcede Pharma	AQ
08/01/24	BioStock: Arcede aims for clinic with TO1	AQ
21/12/23	BioStock: Arcede Pharma appoints acting CEO	AQ
20/11/23	BioStock: Arcede proceeds to stability study in collaboration with Iconovo	AQ
16/11/23	Arcede Pharma and Iconovo take the next step in the development of a new treatment for COPD	AQ
14/11/23	BioStock: Arcede Pharma approaches clinical trial after toxicological results	AQ
10/10/23	BioStock: Arcede Pharma's CEO on the right issue outcome	AQ
15/08/23	BioStock: Arcede hopes to reach larger market than existing drugs	AQ
30/05/23	BioStock Life Science Spring Summit with Arcede Pharma	AQ
17/05/23	BioStock: Arcede approaching dosing in tox study	AQ
28/04/23	BioStock: RSV drugs give hope to COPD patients	AQ
31/03/23	Funding received from Swelife for the development of a new treatment for COPD and severe asthma	AQ
23/03/23	BioStock: Update from Arcede Pharma CEO	AQ
16/03/23	BioStock Investor Meeting with Arcede Pharma	AQ
15/02/23	BioStock: Arcede Pharma looks ahead with strengthened team	AQ
26/01/23	Notice of allowance for patent application of RCD405 in Canada	AQ
07/12/22	BioStock: Arcede Pharma prepares for clinical studies	AQ
28/11/22	BioStock: Arcede Pharma's RCD405 well tolerated	AQ
03/11/22	BioStock: Arcede Pharma share under pressure despite development progress	AQ
28/09/22	BioStock Investor Meeting: Interview with Arcede Pharma	AQ
27/09/22	BioStock: Arcede Pharma reports on the first quarter	AQ
22/09/22	BioStock Investor Meeting: Arcede Pharma presents	AQ
16/08/22	BioStock: Arcede wants to renew the market for respiratory drugs	AQ